0000914475-24-000111.txt : 20240417 0000914475-24-000111.hdr.sgml : 20240417 20240417171953 ACCESSION NUMBER: 0000914475-24-000111 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240415 FILED AS OF DATE: 20240417 DATE AS OF CHANGE: 20240417 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BENEVICH ERIC CENTRAL INDEX KEY: 0001643653 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 24852003 MAIL ADDRESS: STREET 1: C/O NEUROCRINE BIOSCIENCES, INC. STREET 2: 12790 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330525145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6027 EDGEWOOD BEND COURT CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 wk-form4_1713388780.xml FORM 4 X0508 4 2024-04-15 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001643653 BENEVICH ERIC 12780 EL CAMINO REAL SAN DIEGO CA 92130 0 1 0 0 Chief Commercial Officer 1 Common Stock 2024-04-15 4 M 0 7231 81.49 A 48009 D Common Stock 2024-04-15 4 S 0 7231 133.3646 D 40778 D Common Stock 2024-04-15 4 M 0 12587 81.05 A 53365 D Common Stock 2024-04-15 4 S 0 12587 133.3646 D 40778 D Non-Qualified Stock Option 81.49 2024-04-15 4 M 0 7231 81.49 D 2028-02-05 Common Stock 7231 26292 D Non-Qualified Stock Option 81.05 2024-04-15 4 M 0 12587 81.05 D 2029-02-07 Common Stock 12587 0 D The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $131.56 to $136.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The option was granted February 5, 2018 and vested in 48 equal monthly installments beginning March 5, 2018. These options will expire ten years from the date of grant on February 05, 2028. The option was granted February 7, 2019 and vested in 48 equal monthly installments beginning March 7, 2019. These options will expire ten years from the date of grant on February 07, 2029. /s/ Darin Lippoldt, Attorney-in-Fact 2024-04-17